GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
57.41
-0.40 (-0.69%)
Apr 16, 2026, 11:56 AM EDT - Market open
GSK Employees
GSK plc had 66,841 employees as of December 31, 2025. The number of employees decreased by 1,788 or -2.61% compared to the previous year.
Employees
66,841
Change (1Y)
-1,788
Growth (1Y)
-2.61%
Revenue / Employee
$657,775
Profits / Employee
$115,096
Market Cap
115.58B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66,841 | -1,788 | -2.61% |
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
| Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
| Dec 31, 2017 | 98,462 | -838 | -0.84% |
| Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
| Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
| Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
| Dec 31, 2013 | 99,451 | -37 | -0.04% |
| Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
| Dec 31, 2011 | 97,389 | 928 | 0.96% |
| Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
| Dec 31, 2009 | 99,913 | 910 | 0.92% |
| Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
| Dec 31, 2007 | 103,483 | 788 | 0.77% |
| Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
| Dec 31, 2005 | 100,728 | 709 | 0.71% |
| Dec 31, 2004 | 100,019 | -900 | -0.89% |
| Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
| Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
| Dec 31, 2001 | 107,470 | -47 | -0.04% |
| Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
| Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
| Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
GSK News
- 3 days ago - GSK Reports Promising Phase I Results for Novel Cancer Treatment - GuruFocus
- 3 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer - Benzinga
- 3 days ago - GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% - GuruFocus
- 3 days ago - GSK Reports Promising Early Data For Experimental Cancer Drug - Benzinga
- 3 days ago - GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer - Nasdaq
- 3 days ago - GSK Shifts Strategy with Five Late-Stage Trials for Promising Cancer Drug - GuruFocus
- 4 days ago - GSK reports promising early results in ovarian and womb cancer drug trial - The Guardian
- 4 days ago - GSK sees blockbuster potential in targeted cancer therapy after promising early data - Reuters